{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:51:36Z","timestamp":1786341096728,"version":"build-2736575974"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jhep.2022.06.024","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:59:08Z","timestamp":1656982748000},"page":"1215-1217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-responders to sofosbuvir\/velpatasvir\/voxilaprevir in the treatment of chronic hepatitis C infection"],"prefix":"10.1016","volume":"77","author":[{"given":"Hamidreza","family":"Karimi-Sari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0447-6607","authenticated-orcid":false,"given":"Mohammad Saeid","family":"Rezaee-Zavareh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwaseun","family":"Falade-Nwulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1126-8128","authenticated-orcid":false,"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.06.024_bib1","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jhep.2020.11.017","article-title":"Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy","volume":"74","author":"Dietz","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.024_bib2","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.024_bib3","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/jvh.13497","article-title":"Resistance-associated substitutions after sofosbuvir\/velpatasvir\/voxilaprevir triple therapy failure","volume":"28","author":"Garcia-Cehic","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2022.06.024_bib4","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.024_bib5","series-title":"HCV Guidance: Recommendations for testing, managing, and treating hepatitis C: Retreatment of persons in whom prior therapy failed","year":"2021"},{"key":"10.1016\/j.jhep.2022.06.024_bib6","first-page":"451","article-title":"Successful fourth line treatment of a relapse patient with chronic hepatitis C virus infection genotype 3a using sofosbuvir, glecaprevir\/pibrentasvir, and ribavirin: a case report","volume":"58","author":"Bernhard","year":"2020","journal-title":"Z\u00a0Gastroenterologie"},{"key":"10.1016\/j.jhep.2022.06.024_bib7","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1002\/hep.31909","article-title":"Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a rescue therapy in difficult-to-treat HCV patients","volume":"74","author":"Meszaros","year":"2021","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.jhep.2022.06.024_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.02.024","article-title":"Glecaprevir\/pibrentasvir+ sofosbuvir+ ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings","author":"Martin","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.06.024_bib9","article-title":"Glecaprevir\/pibrentasvir\u00a0+ sofosbuvir\u00a0+ ribavirin as a salvage regimen after Sofosbuvir\u00a0+ Velpatasvir\u00a0+ Voxilaprevir re-treatment failure","author":"Tergast","year":"2021","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2022.06.024_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.04.017","article-title":"Reply to\" Glecaprevir\/pibrentasvir+ sofosbuvir+ ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings\"","author":"Dietz","year":"2021","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822029221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822029221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:48:49Z","timestamp":1759175329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822029221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0168827822029221"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.06.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-responders to sofosbuvir\/velpatasvir\/voxilaprevir in the treatment of chronic hepatitis C infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}